IRD
Opus Genetics, Inc.
Key Financials
Revenue
$14.2M
↑ 29.1%
Operating Income
$-38599000
↑ 37.8%
Net Income
$-49591000
↑ 13.8%
EPS (Diluted)
$-0.80
↑ 62.8%
Total Liabilities
$34.9M
↑ 208.9%
Shareholders' Equity
$15.3M
↑ 128.3%
Total Assets
$50.2M
↑ 36.3%
Long-term Debt
$35.3M
N/A
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 10/2/2026 | View on SEC |
| 4 | 9/11/2026 | View on SEC |
| 8-K | 9/11/2026 | View on SEC |
| 8-K | 9/9/2026 | View on SEC |
| 4 | 9/8/2026 | View on SEC |
| 4 | 9/8/2026 | View on SEC |
| 144 | 9/3/2026 | View on SEC |
| EFFECT | 8/14/2026 | View on SEC |
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | IRD |
| Company Name | Opus Genetics, Inc. |
| CIK | 1228627 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (984) 884-6030 |